- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cspc Pharmaceutical Group Ltd.
Industry Sector: HealthTechnology
CEO: Cui Long Zhang
Number Of Employees: 21,400
Enterprise Value: $6,384,743,776
PE Ratio: 21.28
Exchange/Ticker 1: HKEX:1093
Exchange/Ticker 2: N/A
Latest Market Cap: $11,400,254,556
BioCentury | Aug 4, 2025
Deals
China momentum continues with Madrigal-CSPC, Arrowhead-Sanofi tie-ups: Deals Report
Plus: Bain, KKR underscore PE interest in biotech
BioCentury | Jul 30, 2025
Data Byte
Busy period for Asia’s dealmakers has HBM, Biocytogen at the top
A leaderboard of deals from Asian biotechs to Western biotechs and multinational pharmas
BioCentury | Jul 23, 2025
Deals
Asia deals: Globalization is open for business
An analysis of East-West deal flow from 2023 to 1H25
BioCentury | Jun 17, 2025
Deals
AZ in AI discovery deal with China’s CSPC: Deals Report
Plus: Biontech acquiring fellow German mRNA play Curevac, Supernus buying Sage, and more
BioCentury | Jun 6, 2025
Product Development
ASCO’s first-in-human studies center on solid tumor surface antigens
BioCentury’s analysis finds immunocytokines, solid tumor CAR Ts and trispecific antibodies thriving in early trials
BioCentury | Apr 23, 2025
Product Development
Degraders, bispecifics define translational trends at AACR
Plus: New targets involving glycosylation, angiogenesis and more
BioCentury | Apr 7, 2025
Data Byte
Hong Kong stocks plunge. More tariffs loom
Previously a bright spot in 2025 markets, Hong Kong stocks take a sharp downturn
BioCentury | Apr 1, 2025
Deals
Novo, Merck each pay $200M for pipeline additions: Deals Report
Pharmas enter nine-figure upfront deals in metabolic, cardiovascular areas; plus, Bluebird will consider competing buyout offer
BioCentury | Feb 25, 2025
Deals
Counteroffer from Tang-backed Concentra could scuttle Acelyrin-Alumis: Deals Report
Plus Radiance gets ROR1 ADC from Cspc, Astrazeneca buys Fibrogen’s China subsidiary and more
BioCentury | Oct 7, 2024
Deals
AstraZeneca, Hong Kong-based CSPC in deal for dyslipidemia therapy
Deals report: Recordati acquires Enjaymo from Sanofi, and updates from BioMarin-Camp4, Editas-DRI and more
Items per page:
1 - 10 of 48